Folia Parasitologica 60[1] 1-6 (2013) | DOI: 10.14411/fp.2013.001

Evaluation of anti-leishmanial effects of killed Leishmania vaccine with BCG adjuvant in BALB/c mice infected with Leishmania major MRHO/IR/75/ER

Hossein Nahrevanian1, Seyedeh Parisa Jafary2, Sara Nemati1, Mahin Farahmand1, Eskandar Omidinia3
1 Department of Parasitology, Pasteur Institute of Iran, Tehran, Iran
2 Islamic Azad University of Oloum Tahghighat, Tehran, Iran
3 Department of Biochemistry, Pasteur Institute of Iran, Tehran, Iran

There are many strategies to control leishmaniasis, but majority of them are inadequate. Killed Leishmania vaccine (KLV) has been applied for its immunogenicity in human and mouse model. Bacillus Calmette-Guerin (BCG) as adjuvant is an immunemodulator inducing humoral and cellular immune responses during zoonotic cutaneous leishmaniasis (ZCL). Both KLV and BCG have been applied for their immune responses in hosts for controlling leishmaniasis. In this study, KLV and BCG were applied to inhibit replication and visceralization of Leishmania major in BALB/c mice. Mice were injected with KLV and BCG, followed by infection with promastigotes of L. major. Six weeks after infection, a small nodule appeared, which was followed by development of a large lesion and visceralization. Effects of KLV and BCG, physiopathological changes, lesion size, delay of lesion formation, proliferation of amastigotes inside macrophages and detection of amastigotes in target organs were studied. Results showed that the KLV had anti-leishmanial activity by reducing lesion size on late infection. In KLV and BCG group, the average number of amastigotes in macrophages was lower than in other groups. Significant reductions in number of amastigotes in both spleen and lymph node were observed, indicating lower visceralization of Leishmania parasites in these target organs. No significant changes were presented in body weights, survival rates and degrees of splenomegaly in test group. It can be concluded that application of KLV and BCG had acceptable efficacy in reduction of skin lesions size and proliferation of parasites, even though a few side-effects were observed. It is indicated that KLV/BSG may have ability to modulate host immune responses against Leishmania parasites and to reduce pathophysiology of the disease during infection.

Keywords: vaccine, KLV, adjuvant, Leishmania major, immunization, Iran

Received: May 11, 2012; Accepted: September 14, 2012; Published: February 14, 2013  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Nahrevanian, H., Jafary, S.P., Nemati, S., Farahmand, M., & Omidinia, E. (2013). Evaluation of anti-leishmanial effects of killed Leishmania vaccine with BCG adjuvant in BALB/c mice infected with Leishmania major MRHO/IR/75/ER. Folia Parasitologica, 60(1), 1-6. doi: 10.14411/fp.2013.001
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abdelhak S., Louzir H., Timm J., Blel L., Benlasfar Z., Lagranderie M., Gheorghiu M., Dellagi K., Gicquel B. 1995: Recombinant BCG expressing the Leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice. Microbiology 141: 1585-1592 Go to original source... Go to PubMed...
    2. Amaral V.F., Teva A., Oliveira-Neto M.P., Silva A.J., Pereira M.S., Cupolillo E., Porrozzi R., Coutinho S.G., Pirmez C., Beverley S.M., Grimaldi G. Jr. 2002: Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease. Mem. Inst. Oswaldo Cruz 97: 1041-1048 Go to original source... Go to PubMed...
    3. Antunes C.M.F., Mayrink W., Magalhaes P.A., Costa C.A., Melo M.N., Dias M., Michalick M.S., William P., Lima A.O., Vieira J.B. 1986: Controlled field trials of a vaccine against new world cutaneous leishmaniasis. Int. J. Epidemiol. 15: 572-580 Go to original source... Go to PubMed...
    4. Castes M., Blackwell J., Trujillo D., Formica S., Cabrera M., Zorrilla G., Rodas A., Castellanos P.L., Convit J. 1994: Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG 1: skin test reactivity, T‑cell proliferation, and interferon-gamma production. Vaccine 12: 1041-1051 Go to original source... Go to PubMed...
    5. Convit J., Castellanos P.L., Rondon A., Pinardi M.E., Ulrich M., Castes M., Bloom B., Garcia L. 1987: Immunotherapy versus chemotherapy in localized cutaneous leishmaniasis. Lancet 1: 401-405 Go to original source... Go to PubMed...
    6. El-On J., Witztum A., Schnur L.F. 1986: Protection of Guinea pigs against cutaneous leishmaniasis by combined infection and chemotherapy. Inf. Immun. 51: 704-706 Go to original source...
    7. Erel O., Kocyigit A., Bulut V., Gurel M.S. 1999: Reactive nitrogen and oxygen intermediates in patients with cutaneous leishmaniasis. Mem. Inst. Oswaldo Cruz 94: 179-183 Go to original source... Go to PubMed...
    8. Garg R., Dube A. 2006: Animal models for vaccine studies for visceral leishmaniasis. Ind. J. Med. Res. 123: 439-454
    9. Green M.S., Kark J.D., Witztum E., Greenblatt C.L., Spira D.T. 1983: Frozen stored L. tropica vaccine: the effect of dose, route for administration and storage on the evolution of clinical lesion. Two field trials in the Israel defense forces. Trans. R. Soc. Trop. Med. Hyg. 77: 152-159. Go to original source... Go to PubMed...
    10. Jamshidi Sh., Avizeh R., Mohebali M., Bokaie S. 2011: Immunotherapy using autoclaved L. major antigens and M. vaccae with Meglumine antimoniate, for the treatment of experimental canine visceral leishmaniasis. Iran. J. Parasitol. 6: 26-34
    11. Kamil A.A., Khalil E.A., Musa A.M., Modabber F., Mukhtar M.M., Ibrahim M.E., Zijlstra E.E., Sacks D., Smith P.G., Zicker F., El-Hassan A.M. 2003: Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guerin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers. Trans. R. Soc. Trop. Med. Hyg. 97: 365-368 Go to original source... Go to PubMed...
    12. Keshavarz Valian H., Khoshabe Abdollah Kenedy L., Nateghi Rostami M., Miramin Mohammadi A., Khamesipour A. 2008: Role of Mycobacterium vaccae in the protection induced by first generation Leishmania vaccine against murine model of leishmaniasis. Parasitol. Res. 103: 21-28 Go to original source... Go to PubMed...
    13. Khalil E.A., Musa A.M., Modabber F., El-Hassan A.M. 2006: Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major + BCG) in children: an extended phase II study. Ann. Trop. Paediatr. 26: 357-361 Go to original source... Go to PubMed...
    14. Klaus S.N., Frankenburg S., Ingber A. 1999: Epidemiology of cutaneous leishmaniasis. Clin. Dermatol. 17: 257-260 Go to original source... Go to PubMed...
    15. Kobets T., Grekov I., Lipoldova M. 2012: Leishmaniasis: prevention, parasite detection and treatment. Curr. Med. Chem. 19: 1443-1474 Go to original source... Go to PubMed...
    16. Latifynia A., Mohaghegh Hazrati S. 2008: Safety and toxicity of a new formulated Leishmania major preliminary vaccine in animal model Balb/c and small white conventional laboratory mice. Tuerk. Parazitol. Dergisi 32: 103-108
    17. Manson-Bahr P.E.C., Apted F.I. 1983: Manson's Tropical Diseases, 18th edition. Bailliere Tindall, London, 843 pp
    18. Mayrink W., da Costa C.A., Magalhaes P.A., Melo M.N., Dias M., Lima A.O., Michalick M.S., William P. 1979: A field trial of a vaccine against American dermal leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 73: 385-387 Go to original source... Go to PubMed...
    19. Mayrink W., Williams P., da Costa C.A., Magalhaes P.A., Melo M.N., Dias M., Oliveira Lima A., Michalick M.S., Ferreira Carvalho E., Barros G.C. 1985: An experimental vaccine against American dermal leishmaniasis: experience in the state of Espirito Santo, Brazil. Ann. Trop. Med. Parasitol. 79: 259-269 Go to original source... Go to PubMed...
    20. Michel M.Y., Fathy F.M., Hegazy E.H., Hussein E.D., Eissa M.M., Said D.E. 2006: The adjuvant effects of IL-12 and BCG on autoclaved Leishmania major vaccine in experimental cutaneous leishmaniasis. J. Egypt. Soc. Parasitol. 36: 159-176
    21. Mohebali M., Javadian E.H., Hashemi-Fesharki R., Mohammad zadeh M., Nadim A., Tahvildar-Bidruni G.H., Mesdaghim A. 1995: Trial of a nonliving crude vaccine against zoonotic cutaneous leishmaniasis. Med. J. Islamic Rep. Iran 8: 211-215
    22. Mohebali M., Khamesipour A., Mobedi I., Zarei Z., Hashemi-Fesharki R. 2004: Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in MeshkinShahr district, I.R. Iran. Vaccine 22: 4097-4100 Go to original source... Go to PubMed...
    23. Momeni A.Z., Jalayer T., Emamjomeh M., Khamesipour A., Zicker F., Ghassemi R.L., Dowlati Y., Sharifi I., Aminjavaheri M., Shafiei A., Alimohammadian M.H., Hashemi-Fesharki R., Nasseri K., Godal T., Smith P.G., Modabber F. 1999: A randomized double-blind, controlled trial of killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 17: 466-472 Go to original source... Go to PubMed...
    24. Nadim A., Javadian E. 1988: Leishmanization in the Islamic Republic of Iran. In: B.C. Walton, P.M. Wijeyaratna and F. Modabber (Eds.), Research on Control Strategies for Leishmaniasis. International Development Research Centre, Toronto, pp. 336-339
    25. Nahrevanian H., Farahmand M., Aghighi Z., Assmar M., Amirkhani A. 2007: Pharmacological evaluation of anti-leishmanial activity by in vivo nitric oxide modulation in Balb/c mice infected with Leishmania major MRHO/IR/75/ER: an Iranian strain of cutaneous leishmaniasis. Exp. Parasitol. 116: 233-240 Go to original source... Go to PubMed...
    26. Nateghi Rostami M., Keshavarz H., Khamesipour A. 2010: Immune response of BALB/c mice against an experimental vaccine of Alum precipitated autoclaved Leishmania major (Alum-ALM) mixed with BCG or Mycobacterium vaccae. Trop. Biomed. 27: 89-102 Go to PubMed...
    27. Noazin S., Khamesipour A., Moulton L.H., Tanner M., Nasseri K., Modabber F., Sharifi I., Khalil E.A., Bernal I.D., Antunes C.M., Smith P.G. 2009: Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine 27: 4747-4753 Go to original source... Go to PubMed...
    28. Pearson R.D., Wheeler D.A., Harrison L.H., Kay H.D. 1983: The immunobiology of leishmaniasis. Rev. Infect. Dis. 5: 907-927 Go to original source... Go to PubMed...
    29. Pereira L.I., Dorta M.L., Pereira A.J., Bastos R.P., Oliveira M.A., Pinto S.A., Galdino H. Jr., Mayrink W., Barcelos W., Toledo V.P., Lima G.M., Ribeiro-Dias F. 2009: Increase of NK cells and proinflammatory monocytes are associated with the clinical improvement of diffuse cutaneous leishmaniasis after immunochemotherapy with BCG/Leishmania antigens. Am. J. Trop. Med. Hyg. 81: 378-383 Go to original source... Go to PubMed...
    30. Roberts W.L., McMurray W.J., Rainey P.M. 1998: Characterization of the antimonial antileishmanial agent meglumine antimoniate (Glucantime). Antimicrob. Agents Chemother. 42: 1076-1082 Go to original source... Go to PubMed...
    31. Salehizadeh E., Nahrvevanian H., Farahmand M., Hajihosseini R., Saghiri R., Khalili G. 2011: In vivo application of killed Leishmania vaccine and Imiquimod as adjuvant in Balb/c mice infected with Leishmania major MRHO/IR/75/ER as Iranian strain. Res. J. Parasitol. 6: 116-126 Go to original source...
    32. Scott P. 2005: Immunologic memory in cutaneous leishmaniasis. Cell Microbiol. 7: 1707-1713 Go to original source... Go to PubMed...
    33. Sharifi I., Fekri A.R., Aflatonian M.R., Khamesipour A., Nadim A., Mousavi M.R., Momeni A.Z., Dowlati Y., Godal T., Zicker F., Smith P.G., Modabber F. 1998: Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 351: 1540-1543 Go to original source... Go to PubMed...
    34. Smrkovski L.L., Larson C.L. 1977a: Antigenic cross-reactivity between Mycobacterium bovis (BCG) and Leishmania donovani. Infect. Immun. 18: 561-562 Go to original source... Go to PubMed...
    35. Smrkovski L.L., Larson C.L. 1977b: Effect of treatment with BCG on the course of visceral leishmaniasis in BALB/c mice. Infect. Immun. 16: 249-257 Go to original source... Go to PubMed...
    36. Soudi S., Hosseini A.Z., Hashemi S.M. 2011: Co-administration of rectal BCG and autoclaved Leishmania major induce protection in susceptible BALB/c mice. Parasite Immunol. 33: 561-571 Go to original source... Go to PubMed...
    37. Stefani M.M., Mueller I., Louis J. 1993: Leishmania major infection in BALB/c mice: protection or exacerbation by treatment with different doses of BCG. Res. Immunol. 144: 233-243 Go to original source... Go to PubMed...
    38. UNDP/World Bank /WHO 1997: Tropical disease research: progress 1995-1996, Thirteenth Programme Report of the UNDP/World Bank/WHO, Special Programme for Research & Training in Tropical Diseases, 149 pp. (http://www.who.int/tdr/ publications/about-tdr/progress-reports/progress-report-95-96/ en/index.html)
    39. Weintraub J., Weinbaum F.I. 1977: The effect of BCG on experimental cutaneous leishmaniasis in mice. J. Immunol. 118: 2288- 2290 Go to original source... Go to PubMed...

    Return to the content